As of January 23, 2025, Lipocine (LPCN) has a market cap of $23.477 million USD. According to our data, Lipocine is ranked No.8535 in global market value.
Year | Market Cap | %Change |
---|---|---|
Jan 23, 2025 | $23.48 M |
-10.04%
|
Dec 31, 2024 | $26.10 M |
74.91%
|
Dec 29, 2023 | $14.92 M |
-58.76%
|
Dec 30, 2022 | $36.18 M |
-59.84%
|
Dec 31, 2021 | $90.10 M |
-27.13%
|
Dec 31, 2020 | $0.12 B |
253.25%
|
Dec 31, 2019 | $35.00 M |
-70.38%
|
Dec 31, 2018 | $0.12 B |
-62.21%
|
Dec 29, 2017 | $0.31 B |
-6.52%
|
Dec 30, 2016 | $0.33 B |
-71.54%
|
Dec 31, 2015 | $1.18 B |
145.82%
|
Dec 31, 2014 | $0.48 B |
-36.24%
|
Dec 31, 2013 | $0.75 B |
100%
|
Name | Market Cap | Market cap difference | Regions |
---|---|---|---|
Eli Lilly
LLY
|
$678.07 B |
0.022 M
|
USA
|
Novo Nordisk A/S
NOVO-B.CO
|
$364.81 B |
95.450 B
|
Denmark
|
Johnson & Johnson
JNJ
|
$349.75 B |
0.001 M
|
USA
|
Novo Nordisk
NVO
|
$335.24 B |
64.098 B
|
Denmark
|
AbbVie
ABBV
|
$299.00 B |
-0.007 M
|
USA
|
Roche
ROG.SW
|
$243.84 B |
38.062 B
|
Switzerland
|
Merck
MRK
|
$242.04 B |
-0.000 M
|
USA
|
AstraZeneca
AZN
|
$211.49 B |
0.007 M
|
UK
|
Novartis
NVS
|
$196.27 B |
-0.007 M
|
Switzerland
|
Pfizer
PFE
|
$147.40 B |
-0.003 M
|
USA
|
Amgen
AMGN
|
$146.98 B |
0.004 M
|
USA
|
Sanofi
SNY
|
$129.14 B |
0.001 M
|
France
|
Gilead Sciences
GILD
|
$115.95 B |
0.002 M
|
USA
|
Bristol-Myers Squibb
BMY
|
$115.79 B |
-0.003 M
|
USA
|
Vertex Pharmaceuticals
VRTX
|
$110.22 B |
0.001 M
|
USA
|
CSL
CSL.AX
|
$82.07 B |
-0.055 B
|
Australia
|
Zoetis
ZTS
|
$75.18 B |
-0.001 M
|
USA
|
Regeneron Pharmaceuticals
REGN
|
$74.73 B |
1.236 B
|
USA
|
Chugai Pharmaceutical
4519.T
|
$68.91 B |
-0.695 B
|
Japan
|
GlaxoSmithKline
GSK
|
$68.21 B |
-0.002 M
|
UK
|
Market Cap | = | LPCN Stock Price | * | LPCN Shares Outstanding |
= | $4.39 | * | 5.35 M | |
= | $23.48 M |